All studies
Nephrology · Biobank · United Kingdom
Xu 2026
Hyperuricemia
ITTSuperiorityAcademia2/5 disclosures
Comparisons
1
In the analysis
1
all comparisons pooled
Target trials
1
Emulations reported
1
2 treatments
Design and methods
- Estimand
- ITT
- Design hypothesis
- Superiority
- Matching / weighting
- 1:4 genetic matching
- Analysis method
- G-computation linear regression
- Missing data
- Complete case
- DAG
- No
- QBA
- No
Data and sample
- Data type
- Biobank
- Data sources
- 1
- Geography
- United Kingdom
- Eligible sample
- 115
- Treated
- 23
- Control
- 92
- Emulations
- 1
- Treatments compared
- 2
Transparency
- Protocol
- No pre-registration
- Preprint
- No preprint
- Data availability
- Unavailable
- Code availability
- Unavailable
- Conflicts of interest
- Declared: None
- Funding
- Declared: Public
- Funders
- British Heart Foundation and NIHR support
The 0-5 count records which disclosures are present. It is not a quality score: a data link does not establish that the data are reusable.
Provenance
- Review key
- 2026_Xu_Losartan
- DOI
- 10.1038/s41440-026-02719-0
- Affiliations
- University of Manchester and UK Biobank collaborators
- Sector
- Academia
- Target trials (study level)
- Six randomized losartan trials